...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >The Outcome of Medical Management of Chronic Subdural Hematoma with Tranexamic Acid - A Prospective Observational Study
【24h】

The Outcome of Medical Management of Chronic Subdural Hematoma with Tranexamic Acid - A Prospective Observational Study

机译：促进糖尿病慢性血管血肿的医学管理的结果 - 预期观察研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: The conservative management of Chronic subdural hematoma (CSDH) is controversial. Many drugs have been tried in the conservative management of CSDH. Tranexamic acid (Txa) is one such drug in the armamentarium for conservative management of CSDH. We conducted a prospective observational study about treatment of CSDH with Txa. Material and methods: The study was conducted over three years. The clinical grading was assessed by the Markwalder grading system. All patients who were relatively and mildly symptomatic and willing for conservative management were recruited for the study. All patients were given Txa in the dosage of 750 mg/day in divided doses. The patients were followed up in the neurosurgery out-patient department. Results: There were 27 patients with 30 CSDH during this period who were treated with Txa. There were 20 cases of primary CSDHs and 7 cases of recurrent CSDHs following surgery that were enrolled in the Txa group. The mean volume of treated CSDH was 135.62 +/- 92.90 SD. The mean thickness of CSDH enrolled in the study was 14.31 +/- 5.47 SD. The mean number of days the patients treated with Txa was 64.83 +/- 24.8 SD. There were no complications in any of the patients. All patients had good resolution of the hematomas, and none of the hematomas progressed during conservative treatment. Conclusion: The conservative management of CSDH with Txa is both a safe and effective alternative in the absence of life-threatening symptoms.
机译：导言：慢性硬膜下血肿（CSDH）的保守治疗存在争议。在保守治疗CSDH的过程中，已经尝试了许多药物。氨甲环酸（Txa）是一种用于保守治疗慢性硬膜下血肿的药物。我们进行了一项关于Txa治疗CSDH的前瞻性观察研究。材料与方法：研究历时三年。临床分级采用Markwalder分级系统进行评估。所有症状相对轻微且愿意保守治疗的患者均被纳入研究。所有患者分次服用750 mg/天的Txa。患者在神经外科门诊部接受随访。结果：在这段时间内，27名患者共30例CSDH，他们接受了Txa治疗。Txa组有20例原发性CSDH和7例术后复发性CSDH。治疗后CSDH的平均体积为135.62+/-92.90 SD。研究中登记的CSDH平均厚度为14.31+/-5.47 SD。患者接受Txa治疗的平均天数为64.83+/-24.8 SD。所有患者均未出现并发症。所有患者的血肿消退良好，在保守治疗期间没有任何血肿进展。结论：在没有危及生命的症状的情况下，保守治疗伴有Txa的CSDH是一种安全有效的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号